Currently out of the existing stock ratings of Navin Jacob, 26 are a HOLD (49.06%), 26 are a BUY (49.06%), 1 are a SELL (1.89%).

Navin Jacob

Work Performance Price Targets & Ratings Chart

Analyst Navin Jacob, carries an average stock price target met ratio of 70.83% that have a potential upside of 15.97% achieved within 260 days. Previously, Navin Jacob worked at UBS.

Navin Jacob’s has documented 129 price targets and ratings displayed on 15 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ABBV, AbbVie at 02-Feb-2025.

Wall Street Analyst Navin Jacob

Analyst best performing recommendations are on MDGL (MADRIGAL PHARMACEUTICALS).
The best stock recommendation documented was for MDGL (MADRIGAL PHARMACEUTICALS) at 1/23/2019. The price target of $119 was fulfilled within 14 days with a profit of $10.04 (9.21%) receiving and performance score of 6.58.

Average potential price target upside

of $31.02 (20.08%) on VRTX (VERTEX PHARMACEUTICALS).
of $28 (50.97%) on ICPT (INTERCEPT PHARMACEUTICALS).
of $23.32 (35.21%) on MRK (MERCK MPANY).

ABBV AbbVie LLY Eli Lilly and Company RPRX Royalty Pharma Plc AGN Allergan plc ICPT Intercept Pharmaceuticals MYL Viatris TEVA Teva Pharma Industries Ltd ADR ZTS Zoetis MRK Merck mpany CELG Celgene REGN Regeneron Pharmaceuticals VRTX Vertex Pharmaceuticals APLT Applied Therapeutics ELAN Elanco Animal Health MDGL Madrigal Pharmaceuticals

Show more stocks

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Geoff Meacham (CITI)